Ajanta Pharma (AJANTPHARM) — Board Meeting

📢 Key Event
Board approved first interim dividend of Rs 32 per share (Rs 400 crore total) and Q1 FY2027 results showing 25% revenue growth.

🔄 What Changed
31% PAT growth to Rs 334 crore and 25% revenue growth to Rs 1,626 crore in Q1 FY2027.

🔮 What's Next
Earnings conference call scheduled for 30 July 2026 at 16:15 IST.

💡 Investor Takeaway
Strong quarterly growth and dividend approval signal healthy cash flow and shareholder returns.

Ajanta Pharma announced its Q1 FY2027 results on 30 July 2026, reporting 25% revenue growth to Rs 1,626 crore and 31% PAT growth to Rs 334 crore. The board approved a first interim dividend of Rs 32 per share (face value Rs 2), totaling Rs 400 crore, with payment starting 18 August 2026 after a 5 August record date. Branded generics drove strong performance across India, Africa, and Asia, while US generics grew 57%. The company also highlighted robust R&D and global market presence.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AJANTPHARM ✨ Ask AI About This

About Ajanta Pharma Limited (AJANTPHARM)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹39,694.55 Cr P/E: 37.6 ROE: 23.3% ROCE: 29.4%

View full AJANTPHARM stock details →

📡 Get AI alerts when AJANTPHARM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AJANTPHARM — Free

💡 Ask AI about this filing

"What is the dividend payout ratio based on FY2027 earnings?" "How does US generic growth compare to peers in Q1 FY2027?" "What is the timeline for new product launches in Africa?"

Ask AI Free →

📊 More AJANTPHARM filings

See all AJANTPHARM filings →

🔥 Also filed on 30 July 2026

AYMSYNTEX AYM Syntex Limited Announcement GILLETTE Gillette India Limited Corporate Action GATEWAY Gateway Distriparks Limited Corporate Action PARADEEP Paradeep Phosphates Limited Financial Results SYRMA Syrma SGS Technology Limited Offer Document MAXESTATES Max Estates Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AJANTPHARM files new disclosures

Track AJANTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.